Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
02 Oct 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2023 Download
29 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 September and 28 September 2023 Download
22 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 September and 21 September 2023 Download
15 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 8 September and 14 September 2023 Download
08 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 September and 7 September 2023 Download

Pages

Date Title Description PDF
08 May 2019 Information on P&L ROVI releases the first quarter 2019 results presentation Download
08 May 2019 Information on P&L ROVI releases the press release related to the first quarter 2019 financial results Download
07 May 2019 Liquidity contracts and specialists ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A.     Download
30 Apr 2019 Liquidity contracts and specialists ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U.     Download
11 Apr 2019 Strategic agreements with third parties The Company releases the press release related to the marketing agreement of Tetridar® in Spain   Download

Pages